Demographic and clinical differences in patients by post-initial immune checkpoint inhibitor treatment
| Characteristic | Chemotherapy n=50 | Immune checkpoint inhibitor n=34 | Other n=30 | P-value |
| Age at diagnosis, median (IQR) | 64.0 (59.5–68.0) | 64.9 (59.1–71.3) | 65.0 (60.7–71.9) | 0.54 |
| Age at initial immune checkpoint inhibitor administration, median (IQR) | 68.0 (61.7–71.9) | 68.5 (62.3–76.3) | 69.3 (63.2–74.6) | 0.52 |
| Race, n (%) | NA | |||
| Non-White* | † | † | † | |
| White | 33 (66.0) | 26 (76.5) | 22 (73.3) | |
| Unknown | † | † | † | |
| Region, n (%) | 0.88 | |||
| Midwest | † | † | † | |
| Northeast | 10 (20.0) | 6 (17.6) | † | |
| South | 16 (32.0) | 10 (29.4) | 13 (43.3) | |
| West | † | † | † | |
| Unknown | † | † | † | |
| Practice type, n (%) | 0.29 | |||
| Academic | 8 (16.0) | 9 (26.5) | 9 (30.0) | |
| Community | 42 (84.0) | 25 (73.5) | 21 (70.0) | |
| ECOG, n (%) | NA | |||
| 0 | 26 (52.0) | 17 (50.0) | 12 (40.0) | |
| 1 | 15 (30.0) | 11 (32.4) | 9 (30.0) | |
| 2 | † | † | † | |
| 3–4 | † | † | † | |
| Unknown | † | † | † | |
| Stage at diagnosis, n (%) | 0.76 | |||
| I | 18 (36.0) | 14 (41.2) | 14 (46.7) | |
| II | † | † | † | |
| III | 12 (24.0) | † | † | |
| IV | 13 (26.0) | 9 (26.5) | 6 (20.0) | |
| Unknown | † | † | † | |
| Prior radiation, n (%) | 0.92 | |||
| Yes | 20 (40.0) | 14 (41.2) | 14 (46.7) | |
| No | 16 (32.0) | 10 (29.4) | 10 (33.3) | |
| Unknown | 14 (28.0) | 10 (29.4) | 6 (20.0) | |
| Prior radiation modality, n (%) | 0.07 | |||
| Vaginal brachytherapy | 6 (12.0) | 6 (17.6) | 8 (26.7) | |
| EBRT with or without concomitant brachytherapy | 9 (18.0) | 8 (23.5) | 6 (20.0) | |
| Unknown | † | † | † | |
| MMR status, n (%) | 0.30 | |||
| MSI-H/dMMR | 10 (20.0) | 12 (35.3) | 12 (40.0) | |
| MSI-L/ pMMR/MSS | 26 (52.0) | 16 (47.1) | 11 (36.7) | |
| Unknown | 14 (28.0) | 6 (17.6) | 7 (23.3) |
*Non-White race category groups Asian, Black, African-American, Hispanic or Latino, and Other for privacy purposes due to small cell numbers.
†Column percentages may not equal 100% due to masking cells with fewer than 5 patients (1.5%) to preserve patient privacy.
dMMR, mismatch repair deficient; EBRT, external beam radiation therapy; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; 1L, first line; 2L, second line; 3L+, third and subsequent lines; MMR, mismatch repair; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stable; pMMR, mismatch repair proficient.